Patients with breast cancer and adjuvant CMF-chemotherapy - Effects on blood coagulation and fibrinolysis;Adjuvante CMF-Chemotherapie bei Patietinnen mit Mammakarzinom-Auswirkungen auf Blutgerinnung und Fibrinolyse

Zentralblatt fur Gynakologie

Volumn 119, Issue 5, 1997, Pages 211-217

  Oberhoff, C ^a   Winkler, U H ^a   Tauchert, A M ^a   Schindler, A E ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

breast cancer; chemotherapy; fribrinolysis; hemostasis; thrombosis

Indexed keywords

CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE; PROTEIN C; TAMOXIFEN; VITAMIN K GROUP; ANTINEOPLASTIC AGENT; BLOOD CLOTTING FACTOR; CISPLATIN; CMF PROTOCOL;

ARTICLE; BLOOD CLOTTING; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG TOXICITY; FEMALE; FIBRINOLYSIS; HUMAN; ADJUVANT CHEMOTHERAPY; BLOOD CLOTTING TEST; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; ISOLATION AND PURIFICATION; LONGITUDINAL STUDY; THROMBOSIS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD COAGULATION; BLOOD COAGULATION FACTORS; BLOOD COAGULATION TESTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; FEMALE; FIBRINOLYSIS; FLUOROURACIL; HUMANS; LONGITUDINAL STUDIES; METHOTREXATE; THROMBOSIS;

EID: 0030612526     PISSN: 00444197     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Bauer K.A. Rosenberg RD: The pathophysiology of the prethrombotic state in humans: Insights gained from studies using markers of hemostatic system activation. Blood 70 (1987) 343-350
2. Bonadonna G, Rosi A, Valagussa P, Banfi A, Veronesi U: The CMF program for operable breast cancer with positive axillary nodes. Cancer 39 (1977) 2904 to 2915
3. Dahlbäck B: The Protein C anticoagulant system: Inherited defects as a basis for venous thrombosis. Thromb Res 77 (1995) 1-43
4. Esmon CT: Protein-C: Biochemistry, physiology, and clinical implications. Blood 62 (1983) 1155-1158
5. Esmon CT, Owen WG: Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. Proc Natl Acad Sci USA 78 (1981) 2249-2252
6. Feffer SE, Carmosino LS, Fox R: Acquired protein C deficiency in patients with breast cancer receiving cyclophosphamide, methotrexate and 5-fluorouracil. Cancer 63 (1989) 1303-1307
7. Francis CW, Marder VJ: Physiologic regulation and pathologic disorders of fibrinolysis. Hum Pathol 18 (1987) 263-274
8. Goodnough LT, Saito H, Manni A, Jones PK, Pearson OH: Increased incidence of thromboembolism in Stage IV breast cancer patients treated with a five-drug chemotherapy regimen - A study of 159 patients. Cancer 54 (1984) 1264-1268
9. Graeff H, Hafter R: Detection and relevance of crosslinked fibrin derivates in blood. Semin Thromb Hemost 8 (1982) 57-68
10. Hyman J, Zimmermann JH: Hepatotoxic effects of oncotherapeutic agents. Prog Liver Dis 7 (1990) 621-642
11. Kluft C, Verheijen JH: Leiden fibrinolysis working party: Blood collection and handling procedures for assesment of tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor (PAI-1). Fibrinolysis 4 (1990) suppl 2, 155-161
12. Levine MN, Hirsh J, Gent M, Arnold A, Warr D, Falanga A, et al.: Double blind randomized trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 343 (1994) 886-889
13. Levine MN, Gent M, Hirsh J, Arnold A, Goodyear MD. Hryniuk W: The thombogenic effect of anticancer drug therapy in women with Stage II breast cancer. N Engl J Med. 318 (1988) 404-407
14. Losito R, Beaudry P. Valderama JC, Cousineau L, Longpre B: Antithrombin III and Factor VIII in patients with neoplasms. Am J Clin Pathol 68 (1977) 258-262
15. Owen WG, Esmon CT: Functional properties of an endothelial cofactor for thrombin-catalyzed activation of protein C. J Biol Chem 257 (1981) 5532-5535
16. Pabinger I, Kyrle PA, Heistinger M, Eichinger S, Wittmann E, Lechner K: The risk of thromboembolism in asymptomatic patients with protein C and protein S deficiency. A prospective cohort study. Thromb Haemost 71 (1994) 441-445
17. Rogers II JS, Murgo AJ, Fontana JA, Raich PC: Chemotherapy for breast cancer decreases plasma protein C and protein S. J Clin Oncol 6 (1988) 276-281
18. Ruggeri ZM: Von Willebrand Factor. FASEB J 7 (1993) 308-316
19. Sagripanti A, Baicchi, Vispi M: The measurement of fibrin D dimer fragment in patients with metastatic breast cancer. In: Advances in management of malignancies. Hrsg. Sagripanti A, Carpi A, Grassi B. Bologna: Monduzzi Edit. 1989, 59-65
20. Saphner T, Tormey DC, Gray R: Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol 9 (1991) 286- 294
21. SAS Intitute Inc.: SAS User's Guide: Statistics, Version 5 Edition. Cary, NC: SAS Inst Inc 1985
22. Wall JG, Weiss RB, Norton L. Perlhoff M, Rice MA, Wood WC: Arterial thrombosis associated with adjuvant chemotherapy for breast carcinoma: A cancer and leukemia group B study. Am J Med 87 (1989) 501-504
23. Wooly PV: Hepatic and pancreatic damage produced by cytotoxic drugs. Cancer Treat Res 10 (1983) 117 to 137